Monitoring Patient Glucose Levels: New Advances in software make it easier
...daily for analysis and can be sent to a secure web site online. The physician can log onto the secure web site to view a graph of daily glucose levels for patients, read a summary of relevant statistics for the ...... or epithelial surfaces, the most common colonized site being the anterior nares. Sites of colonization are important not only as a source of subsequent infection, but also serve as a reservoir for transmission. Although frequent antibiotic use in healthcare settings selects for resistant flora, genetic...Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
...ty results. POCT places a burden on department and site directors to properly identify the training needs of non-laboratorians, and to ensure that they are met. Additionally, non-laboratorian staff trained on POCT methods must be monitored following the trainings in order to insure their competency with t......y providingeducational information through its Web site at <a target="_blank"href="http://www.aaaai.org/">http://www.aaaai.org . CONTACT: Natalie Lemke, , or Amber Johnson,, +1-414-272-6071,both of the AAAAI <a target="_blank" href="mailto:nlemke@aaaai.org">nlemke@aaaai.org <a target...Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
...ated with AGGRASTATR occurs at the arterial access site forcardiac catheterization. Fatal bleedings have been reported.AGGRASTATR should be used with caution in patients with plateletcount less than 150,000/mm3, in patients with hemorrhagicretinopathy and in patients in chronic hemodialysis. BecauseAGGRAS......remaining three events consisted of mild injection site erythema (redness) that occurred on the day of the co-injection and resolved within one or two days. As a spreading agent, hyaluronidase has traditionally been usedto accelerate the delivery of drugs and fluids, including localanesthetic......the Anticalin(R) candidate is viamodulation of the site of binding for multiple ligands. "This important milestone demonstrates the exciting potential ofAnticalin(R)-based products for the treatment of respiratorydisease," said Dr Andreas Hohlbaum, Director of Science andPreclinical Development of Pieris......mation about AVI is available on the company's Web site athttp://www.avibio.com. About Cook Medical Cook Medical was the first company to introduce interventionaldevices in the United States. Today, the company participates inall global markets, integrating device design, biopharma, gene andcell thera...Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
...ugh the Investor Relations section ofAccelrys' web site at www.accelrys.com or by visiting the followingweb address: http://www.wsw.com/webcast/ceut6/accl/. To learn more about C.E. Unterberg, Towbin, please visitwww.unterberg.com. About Accelrys, Inc. Accelrys develops and commercializes Scientific Bu......the presentation will be available on Inspire'sweb site at www.inspirepharm.com. An archived version of thewebcast presentation will also be available through this link for alimited time following the conference. About Inspire Inspire is a biopharmaceutical company dedicated to discovering,developing an...Tercica to Present at Investment Conferences
...visiting the Investors section of the Company'sWeb site at www.tercica.com. An archived presentation will beavailable on the Web site for 21 days. Tercica also announced management's participation in the PacificGrowth Equities One on...Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
...ks will also be available through theCompany's web site for a limited time following the conference. About Micromet, Inc. (<a target="_blank" href="http://www.micromet-inc.com/">www.micromet-inc.com ) Micromet, Inc. is a biopharmaceutical company focusing on thedevelopment of novel, proprietary ...SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
...theInvestor Relations section of the Company's Web site at <a target="_blank" href="http://www.supergen.com/">http://www.supergen.com . The webcastwill be archived for 90 days. About SuperGen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceuticalcompany dedicated to the discovery, rapid dev......hnson & Johnson, please visit theCompany's web site at www.jnj.com. Contact For Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Ernie Knewitz, 908-927-2953 <a target="_blank" href="mailto:eknewitz@prdus.jnj.com">eknewitz@prdus.jnj.com or Steven Cooper, 415-486-3264 &...Stanford Researchers Find Brain Pathway of Depression in Rats
...tanford. For moreinformation, please visit the Web site of the medical center'sOffice of Communication & Public Affairs athttp://mednews.stanford.edu. Contact Stanford University Medical Center Print Media: Mitzi Baker, 650-725-2106 <a target="_blank" href="mailto:mabaker@stanford.edu">mab......Formore information on Suven, please visit our Web site at <a target="_blank" href="http://www.suven.com/">http://www.suven.com Risk Statement: Except for historical information, all of the statements,expectations and assumptions, including expectations andassumptions, contained in this news r......esearch at Mayo Clinic Cancer Center,visit the Web site at <a target="_blank" href="http://cancercenter.mayo.edu/">http://cancercenter.mayo.edu .<a target="_blank" href="http://www.mayoclinic.org/news2007-rst/4117.html?src=email-release">http://www.mayoclinic.org/news2007-rst/4117.html?src...... showed that when it is locallyadministered to the site of pain, there appears to be limitedsystemic exposure. Its short duration of systemic exposure (hours)relative to the long duration of analgesia (12 weeks) resultingfrom a single treatment course of Adlea is particularly importantin this typically el......" The poster will be available on Labopharm's web site (<a target="_blank" href="http://www.labopharm.com/">www.labopharm.com ) onMonday, July 2, 2007 following conclusion of the Forum. In addition, representatives of the Company will be atLabopharm's corporate booth to promote its once-daily tr......tanford. For moreinformation, please visit the Web site of the medical center'sOffice of Communication & Public Affairs athttp://mednews.stanford.edu. Ranked as one of the best pediatric hospitals in the nation byU.S.News & World Report and Child magazine, Lucile PackardChildren's Hospital at Sta......land. Formore information, visit the company's Web site at <a target="_blank" href="http://www.medimmune.com/">http://www.medimmune.com . About Abbott Abbott is a global, broad-based health care company devoted tothe discovery, development, manufacture and marketing ofpharmaceuticals and medical......FDA. For further information,visit the Company Web site at www.biovest.com. About Accentia Biopharmaceuti...try.For further information, visit the Company Web site atwww.accentia.net. Forward-Looking Statements Statements in this release that are not strictly hi......tollfree 800-833-3533 or by visiting Cytogen's web site atwww.cytogen.com. The Company's website is not part of this pressrelease. This press release contains certain "forward-looking" statementswithin the meaning of the Private Securities Litigation Reform Actof 1995 and Section 21E of the Securities Ex......try.For further information, visit the Company Web site atwww.accentia.net. Forward-Looking Statements Statements in this release that are not strictly historical innature constitute "forward-looking statements." Such statementsinclude, but are not limited to, statements about Revimmune(TM)SinuNase(TM),.......niddk.nih.gov/publications/health_risks.htm . Web site accessed May 2007. For further information, please contact: Media: Investors: Media: An Phan Tel (on-site): 609-558-0420 Tel (office): 609-987-4893 Christian Qvist Frandsen Tel (direct): (1) 609 919 7937 ...... more information, please visit Phosphagenics' web site at<a target="_blank" href="http://www.phosphagenics.com/">http://www.phosphagenics.com CONTACT: Company, Dr. Esra Ogru, Executive Vice PresidentResearch &Development, +1-646-706-2155, or Harry Rosen,President and CEO,+1-646-715-3581, bo...HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
...amp;Exchange Commission also maintains an Internet site that containsreports, proxy and information statements, and other informationregarding issuers that file electronically with the U.S. Securities& Exchange Commission at http://www.sec.gov. The Company makesno commitment to publicly release the re......ficacious in preclinical animal studies. Injection site reactionswere the most common adverse events repor... information about Sangamo, visitthe company's web site at <a target="_blank" href="http://www.sangamo.com/">http://www.sangamo.com . This press re......sociated withinsulin therapy may include injection site reactions (on average3-4 percent of patients in cl...n.niddk.nih.gov/publications/health_risks.htm .Web site accessed May 2007. CONTACT: Media, An Phan, +1-609-558-0420, or +1-609-987-4893,orInvestors, Christ...Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
... thereby preventing thedegradation of GLP-1 at the site of action. Unbound ARI-2243 thenundergoes a unique soft drug inactivation as it passes through thegut and into the systemic circulation, which limits the exposure ofthe active species to unwanted targets, such as DPP 8 and 9. Theconversion product, A...... as a deep intra-muscularinjection, with injection site pain and potential irritation andinfection. CRINONE 8% bioadhesive vaginal gel is self-administeredat home once a day using a convenient, patient-friendly, pre-filledapplicator." The full in-press article is available for purchase athttp://www.ferts......armaceuticals may be obtained through Bentley'sweb site at www.bentleypharm.com. Safe Harbor Statement under the Private Securities LitigationReform Act of 1995: This press release contains forward lookingstatements, including without limitation, statements regardingBentley's Nasulin intranasal insulin p...VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
...trials andproducts, please visit the company's web site at www.vivus.com. Certain statements in this press release are forward-lookingwithin the meaning of the Private Securities Litigation Reform Actof 1995. These statements may be identified by the use offorward-looking words such as "anticipate," "bel...Researchers Discover Gene For Rare Skin Disorder
...ion. For moreinformation, visit the Institutes Web site at <a target="_blank"href="http://www.nichd.nih.gov/">http://www.nichd.nih.gov . The National Institutes of Health (NIH) — The Nation'sMedical Research Agency — includes 27 Institutes andCenters and is a component of the U.S. D...AMIA Announces 2008 Summit on Translational Bioinformatics
...ional bioinformatics activities,visit the AMIA web site at: <a target="_blank" href="http://www.amia.org/">http://www.amia.org . Contact: Tia Abner 301-657-1291 ext. 105 tia@amia.org About AMIA The American Medical Informatics Association (AMIA) is aprofessional......ges while takingACTOS. Please visit the ACTOS Web site at <a target="_blank" href="http://www.actos.com/">www.actos.com for Complete PrescribingInformation. Takeda Pharmaceuticals North America, Inc. Based in Deerfield, Ill., Takeda Pharmaceuticals North America,Inc., is a wholly owned subsidi......r core scaffold provides a highlyselective binding site with high structural plasticity and anextensive binding surface comparable to that achieved withantibodies. The adaptability of the Anticalin(R) scaffold hasalready allowed Pieris to develop therapeutic and diagnosticproduct candidates with custom de......T-cells. The safety profilerevealed only injection site mild reactions and no severe adversereactions related to T-cell vaccination. Both Phase I/II clinical studies have demonstrated that T-cellvaccination depletes myelin reactive T-cells in peripheral blood.In the extension study patient population, t...Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
... access thelive webcast, please log on to Amylin's site approximately 15minutes prior to the presentation to register and download anynecessary audio software. More information about ADA can be found at<a target="_blank" href="http://scientificsessions.diabetes.org/">http://scientificsessions...Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
...rnet fromthe investor section of the company's Web site or by dialing thenumbers listed below. A detailed PowerPoint presentation willaccompany the webcast. Conference Call Details: Dial-In: (800) 291-5365 (U.S.) (617) 614-3922 (International) ......ined in the plasma and in the liver, the principal site of HCVreplication. "The current standard of care is inadequate for many chronic HCVpatients, including about half of those with genotype 1 disease,"said Steve Worland, Ph.D., president, Pharmaceuticals. "We believeANA598 possesses favorable characte......nt may vary based on a number of factors,including site initiation and patient enrollment rates. About Pe...nd theinvestors/media section of the Company's web site at <a target="_blank" href="http://www.allos.com/">http://www.allos.com andwill be archived...Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
...tration (badtaste, throat irritation, instillation site reaction, nasalerythema, nasal irritation) were more common with Rylomine orintranasal placebo than the intravenous morphine groups. Generalsystemic adverse events related to active drug were similar acrossmorphine treatment groups regardless of rout...Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
...ontact the Company at 919-862-1000or visit our web site at www.salix.com. Information on our web siteis not incorporated in our SEC filings. Please Note: This press release contains forward-lookingstatements regarding future events. These statements are justpredictions and are subject to risks and uncert......ther information are available onthe company's Web site at <a target="_blank" href="http://www.abbott.com/">http://www.abbott.com . CONTACT: International Media, Kellie Harris, +1-847-937-9789, orU.S.Media, Elizabeth Shea, +1-847-935-2211, or Financial, JohnThomas,+1-847-938-2655, all of Abbott ...Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
... are dry mouth, dysphagia, dyspepsia, andinjection site pain. These adverse events are generally mild tomoderate, transient, self-resolving, and more common with higherdoses. MYOBLOC is supplied as a ready-to-use, injectable solutionin three single-dose vial sizes of 0.5 mL (2500 U), 1.0 mL (5000U), and 2......e company is based in Kenilworth, N.J., and itsWeb site is <a target="_blank" href="http://www.schering-plough.com/">www.schering-plough.com . SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this pressrelease contains certain "forward-looking" statements within themeaning of the Private Sec...Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study
...e company is based in Kenilworth, N.J.,and its Web site is <a target="_blank" href="http://www.schering-plough.com/">www.schering-plough.com SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this pressrelease contains certain "forward-looking" statements within themeaning of the Private Secu......f lymphoma is unknown-- ENBREL can cause injection site reaction-- In a medical study of patients with JRA, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adults -- The kinds of infections reported were generally mild and similar to those usually se......hat is intended for transplantationinto the lesion site of patients with spinal cord injury to inducetissue repair. Geron's development plan for the product calls forthe filing of an Investigational New Drug (IND) Application withthe U.S. Food and Drug Administration later this year pending theoutcome of ......lopment programs, visit the Company's Internet web site at<a target="_blank" href="http://www.vionpharm.com/">www.vionpharm.com . This news release contains forward-looking statements. Suchstatements are subject to certain risk factors which may causeVion's plans to differ or results to vary from...Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients
...lease visit theEuropean Hematology Association Web site at <a target="_blank"href="http://congress.ehaweb.org/12th">http://congress.ehaweb.org/12th . About PNH PNH is an acquired genetic blood disorder defined by hemolysis,in which patients' red blood cells are destroyed by complement, acomponen......the Investor Relations sectionof the Company's Web site by clicking on Presentations. Comparison of Pharmacokinetics and Pharmacodynamics of CombinedImmediate- and Extended-Release (IR+ER) Carbidopa/LevodopaFormulations (VADOVA IR+ER) with IR Carbidopa/Levidopa andControlled-Release Carbidopa/Levodopa in ...Prana Biotechnology Presents New Key Findings on PBT2
...gy. For further information, please visit our web site at <a target="_blank" href="http://www.pranabio.com/">www.pranabio.com <<a target="_blank" href="http://www.pranabio.com/">http://www.pranabio.com/ > . Forward Looking Statements This press release contains "forward-looking ...Dynogen Reports Positive Results in Phase 1B GERD Study
...ct candidate remains availableat the desired local site of action. A recently completed Phase 2study of the candidate as a treatment for IBS-c demonstrated anoverall clinical response rate of 54% in patients receiving a doseof 1.4 mg t.i.d. compared to a 15% clinical response rate forpatients receiving pl......an toll-free number 1 877680-4500 or visit our Web site at <a target="_blank" href="http://www.neurochem.com/">www.neurochem.com . (1) Cochran-Mantel-Haenszel row mean-scores test (2) Cox proportional-hazards analysis. This news release contains forward-looking statements regardingeprodisate (K......t site, withthe most frequent being mild injection site pain. Objective tumor responses, defined as 50% t...howed activity in untreated tumors distantfrom the site of administration of the therapy, including onesubject showing shrinkage and disappearance of lung t...Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
...rugs can be givensafely to patients, can reach the site of action in cancer cellsand are potent enough to induce clinically relevant benefits, evenwhen given for only a brief period. This is encouraging for therapidly advancing new field of RNA targeted medicines and for thefuture of RNA Antagonists in pa...Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
...ks after therapy. Results from the Goshen study site were reported at the meeting.Eleven patients, of w...MUC1 antigen targeted by PAM4, and asingle binding site for the histamine-succinyl-glycine (HSG)peptide. Initial therapy studies showed that pretargeting wi...Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
...tthe U.S. Securities and Exchange Commission's web site at<a target="_blank" href="http://www.sec.gov/">http://www.sec.gov , at AstraZeneca'swebsite at <a target="_blank" href="http://www.astrazeneca.com/">http://www.astrazeneca.com or atMedImmune's website at <a target="_blank" href=...